Vangjeli相关文献与解析，生知库 | 链接生命科学的每一步

Chantal M Ferguson, Bruno M D C Godinho, Dimas Echeverria, Matthew Hassler, Lorenc Vangjeli, Jacquelyn Sousa, Nicholas McHugh, Julia Alterman, Vignesh Hariharan, Pranathi Meda Krishnamurthy, Jonathan Watts, Eveny Rogaev, Anastasia Khvorova

神经

发表日期：2024

文献求助收藏

Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease

利用二价siRNA沉默ApoE基因可改善阿尔茨海默病中的淀粉样蛋白负荷并激活免疫反应通路

期刊:Alzheimers & Dementia

影响因子:13

doi:10.1002/alz.13703

Chantal M Ferguson ，Samuel Hildebrand ，Bruno M D C Godinho ，Julianna Buchwald ，Dimas Echeverria ，Andrew Coles ，Anastasia Grigorenko ，Lorenc Vangjeli ，Jacquelyn Sousa ，Nicholas McHugh ，Matthew Hassler ，Francesco Santarelli ，Michael T Heneka ，Evgeny Rogaev ，Anastasia Khvorova

Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies

蛋白质语言模型能够预测单特异性、双特异性和重链抗体的多反应性

期刊:Antibody Therapeutics

影响因子:

doi:10.1093/abt/tbae012

Xin Yu, Kostika Vangjeli, Anusha Prakash, Meha Chhaya, Samantha J Stanley, Noah Cohen, Lili Huang

信号转导

发表日期：2024

文献求助收藏

Application of In vitro transcytosis models to brain targeted biologics

将体外胞吞作用模型应用于靶向脑组织的生物制剂

期刊:PLoS One

影响因子:2.9

doi:10.1371/journal.pone.0289970

Kangwen Deng ，Yifeng Lu ，Sjoerd J Finnema ，Kostika Vangjeli ，Junwei Huang ，Lili Huang ，Andrew Goodearl

神经科学

发表日期：2023

文献求助收藏

RNAi-based modulation of IFN-γ signaling in skin

基于RNAi的皮肤IFN-γ信号通路调控

期刊:Molecular Therapy

影响因子:12.1

doi:10.1016/j.ymthe.2022.04.019

Qi Tang ，Jacquelyn Sousa ，Dimas Echeverria ，Xueli Fan ，Ying-Chao Hsueh ，Khashayar Afshari ，Nicholas MeHugh ，David A Cooper ，Lorenc Vangjeli ，Kathryn Monopoli ，Ken Okamura ，Annabelle Biscans ，Adam Clauss ，John E Harris ，Anastasia Khvorova

An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis

针对非酒精性脂肪性肝炎遗传性肥胖小鼠模型的肝脏 DGAT2 的 RNAi 疗法

期刊:Molecular Therapy

影响因子:12.1

doi:10.1016/j.ymthe.2021.11.007

Batuhan Yenilmez, Nicole Wetoska, Mark Kelly, Dimas Echeverria, Kyounghee Min, Lawrence Lifshitz, Julia F Alterman, Matthew R Hassler, Samuel Hildebrand, Chloe DiMarzio, Nicholas McHugh, Lorenc Vangjeli, Jacquelyn Sousa, Meixia Pan, Xianlin Han, Michael A Brehm, Anastasia Khvorova, Michael P Czech

Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans

由自然发生的基因变异导致的全身性硬骨蛋白下调，或在动脉粥样硬化斑块中局部性的硬骨蛋白下调，与人类心血管事件无关。

期刊:Journal of Bone and Mineral Research

影响因子:5.9

doi:10.1002/jbmr.4287

Holdsworth, Gill; Staley, James R; Hall, Peter; van Koeverden, Ian; Vangjeli, Ciara; Okoye, Remi; Boyce, Rogely W; Turk, James R; Armstrong, Martin; Wolfreys, Alison; Pasterkamp, Gerard

2'-O-Methyl at 20-mer Guide Strand 3' Termini May Negatively Affect Target Silencing Activity of Fully Chemically Modified siRNA

20 聚体引导链 3' 末端的 2'-O-甲基可能会对完全化学修饰的 siRNA 的靶标沉默活性产生负面影响

期刊:Molecular Therapy-Nucleic Acids

影响因子:6.5

doi:10.1016/j.omtn.2020.05.010

Sarah M Davis, Jacquelyn Sousa, Lorenc Vangjeli, Matthew R Hassler, Dimas Echeverria, Emily Knox, Anton A Turanov, Julia F Alterman, Anastasia Khvorova

表观遗传

发表日期：2020

文献求助收藏

Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A(2) formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

在盎格鲁-斯堪的纳维亚心脏结局试验（ASCOT）中，PPARGC1B 和 CNTN4 的基因变异与血栓素 A(2) 的形成以及心血管事件无进展生存期相关。

期刊:Atherosclerosis

影响因子:5.7

doi:10.1016/j.atherosclerosis.2017.12.013

McCarthy, Nina S; Vangjeli, Ciara; Surendran, Praveen; Treumann, Achim; Rooney, Cathy; Ho, Emily; Sever, Peter; Thom, Simon; Hughes, Alun D; Munroe, Patricia B; Howard, Philip; Johnson, Toby; Caulfield, Mark; Shields, Denis C; O'Brien, Eoin; Fitzgerald, Desmond J; Stanton, Alice V

Functional confirmation that the R1488* variant in SCN9A results in complete loss-of-function of Na(v)1.7

功能性证实，SCN9A 中的 R1488* 变异会导致 Na(v)1.7 完全丧失功能。

期刊:BMC Medical Genetics

影响因子:

doi:10.1186/s12881-018-0643-4

He, Wen; Young, Gareth T; Zhang, Baohong; Cox, Peter J; Cho, Lily Ting-Yin; John, Sally; Paciga, Sara A; Wood, Linda S; Danziger, Nicolas; Scollen, Serena; Vangjeli, Ciara

发表日期：2018

文献求助收藏

A combinatorial approach for achieving CNS-selective RNAi

实现中枢神经系统选择性 RNAi 的组合方法

Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease

利用二价siRNA沉默ApoE基因可改善阿尔茨海默病中的淀粉样蛋白负荷并激活免疫反应通路

Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies

蛋白质语言模型能够预测单特异性、双特异性和重链抗体的多反应性

Application of In vitro transcytosis models to brain targeted biologics

将体外胞吞作用模型应用于靶向脑组织的生物制剂

RNAi-based modulation of IFN-γ signaling in skin

基于RNAi的皮肤IFN-γ信号通路调控

An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis

针对非酒精性脂肪性肝炎遗传性肥胖小鼠模型的肝脏 DGAT2 的 RNAi 疗法

Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans

由自然发生的基因变异导致的全身性硬骨蛋白下调，或在动脉粥样硬化斑块中局部性的硬骨蛋白下调，与人类心血管事件无关。

2'-O-Methyl at 20-mer Guide Strand 3' Termini May Negatively Affect Target Silencing Activity of Fully Chemically Modified siRNA

20 聚体引导链 3' 末端的 2'-O-甲基可能会对完全化学修饰的 siRNA 的靶标沉默活性产生负面影响

Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A(2) formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

在盎格鲁-斯堪的纳维亚心脏结局试验（ASCOT）中，PPARGC1B 和 CNTN4 的基因变异与血栓素 A(2) 的形成以及心血管事件无进展生存期相关。

Functional confirmation that the R1488* variant in SCN9A results in complete loss-of-function of Na(v)1.7

功能性证实，SCN9A 中的 R1488* 变异会导致 Na(v)1.7 完全丧失功能。